|
1
|
Bacci G, Gherlinzoni F, Picci P, et al:
Adriamycin-methotrexate high dose versus adriamycin-methotrexate
moderate dose as adjuvant chemotherapy for osteosarcoma of the
extremities: a randomized study. Eur J Cancer Clin Oncol.
22:1337–1345. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Burdach S, van Kaick B, Laws HJ, Ahrens S,
Haase R, Körholz D, Pape H, Dunst J, Kahn T, Willers R, et al:
Allogeneic and autologous stem-cell transplantation in advanced
Ewing tumors. An update after long-term follow-up from two centers
of the European Intergroup study EICESS Stem-Cell Transplant
Programs at Düsseldorf University Medical Center, Germany and St
Anna Kinderspital, Vienna, Austria. Ann Oncol. 11:1451–1462. 2000.
View Article : Google Scholar
|
|
3
|
Kong CB, Kim MS, Lee SY, Cho WH, Song WS,
Lee JA, Yoo JY, Chung SH and Jeon DG: Prognostic effect of
diaphyseal location in osteosarcoma: A cohort case-control study at
a single institute. Ann Surg Oncol. 16:3094–3100. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ferrari S, Smeland S, Mercuri M, Bertoni
F, Longhi A, Ruggieri P, Alvegard TA, Picci P, Capanna R, Bernini
G, et al Italian and Scandinavian Sarcoma Groups: Neoadjuvant
chemotherapy with high-dose ifosfamide, high-dose methotrexate,
cisplatin, and doxorubicin for patients with localize1d
osteosarcoma of the extremity: A joint study by the Italian and
Scandinavian Sarcoma Groups. J Clin Oncol. 23:8845–8852. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee JA, Choi SY, Kang HJ, Lee JW, Kim H,
Kim JH, Sung KW, Shin HY, Ahn HS and Park KD: Treatment outcome of
osteosarcoma after bilateral retinoblastoma: A retrospective study
of eight cases. Br J Ophthalmol. 98:1355–1359. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Su Y, Sun CM, Chuang HH and Chang PT:
Studies on the cytotoxic mechanisms of ginkgetin in a human ovarian
adenocarcinoma cell line. Naunyn Schmiedebergs Arch Pharmacol.
362:82–90. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang YQ, Wang MY, Fu XR, Peng-Yu, Gao GF,
Fan YM, Duan XL, Zhao BL, Chang YZ and Shi ZH: Neuroprotective
effects of ginkgetin against neuro-injury in Parkinson's disease
model induced by MPTP via chelating iron. Free Radic Res. Jul
1–2015.Epub ahead of print.
|
|
8
|
Lim H, Son KH, Chang HW, Kang SS and Kim
HP: Effects of anti-inflammatory biflavonoid, ginkgetin, on chronic
skin inflammation. Biol Pharm Bull. 29:1046–1049. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang Y, Shi S, Wang Y and Huang K:
Target-guided isolation and purification of antioxidants from
Selaginella sinensis by offline coupling of DPPH-HPLC and HSCCC
experiments. J Chromatogr B Analyt Technol Biomed Life Sci.
879:191–196. 2011. View Article : Google Scholar
|
|
10
|
You OH and Kim SH, Kim B, Sohn EJ, Lee HJ,
Shim BS, Yun M, Kwon BM and Kim SH: Ginkgetin induces apoptosis via
activation of caspase and inhibition of survival genes in PC-3
prostate cancer cells. Bioorg Med Chem Lett. 23:2692–2695. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Iwata S, Ishii T, Kawai A, Hiruma T,
Yonemoto T, Kamoda H, Asano N and Takeyama M: Prognostic factors in
elderly osteosarcoma patients: A multi-institutional retrospective
study of 86 cases. Ann Surg Oncol. 21:263–268. 2014. View Article : Google Scholar
|
|
12
|
Boye K, Del Prever AB, Eriksson M, Saeter
G, Tienghi A, Lindholm P, Fagioli F, Skjeldal S, Ferrari S and Hall
KS: High-dose chemotherapy with stem cell rescue in the primary
treatment of metastatic and pelvic osteosarcoma: Final results of
the ISG/SSG II study. Pediatr Blood Cancer. 61:840–845. 2014.
View Article : Google Scholar
|
|
13
|
Wang X, Goldstein D, Crowe PJ and Yang JL:
Impact of STAT3 inhibition on survival of osteosarcoma cell lines.
Anticancer Res. 34:6537–6545. 2014.PubMed/NCBI
|
|
14
|
Salas S, Jiguet-Jiglaire C, Campion L,
Bartoli C, Frassineti F, Deville JL, Maues De Paula A, Forest F,
Jézéquel P, Gentet JC, et al: Correlation between ERK1 and STAT3
expression and chemoresistance in patients with conventional
osteosarcoma. BMC Cancer. 14:6062014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen H, Aksoy I, Gonnot F, Osteil P, Aubry
M, Hamela C, Rognard C, Hochard A, Voisin S, Fontaine E, et al:
Reinforcement of STAT3 activity reprogrammes human embryonic stem
cells to naive-like pluripotency. Nat Commun. 6:70952015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yu H, Lee H, Herrmann A, Buettner R and
Jove R: Revisiting STAT3 signalling in cancer: New and unexpected
biological functions. Nat Rev Cancer. 14:736–746. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu J, Wei W, Guo CA, Han N, Pan JF, Fei T
and Yan ZQ: Stat3 upregulates leucine-rich repeat-containing g
protein-coupled receptor 4 expression in osteosarcoma cells. Biomed
Res Int. 2013:3106912013.
|
|
18
|
Jeon YJ, Jung SN, Yun J, Lee CW, Choi J,
Lee YJ, Han DC and Kwon BM: Ginkgetin inhibits the growth of DU-145
prostate cancer cells through inhibition of signal transducer and
activator of transcription 3 activity. Cancer Sci. 106:413–420.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huang J, Lyu H, Wang J and Liu B: MicroRNA
regulation and therapeutic targeting of survivin in cancer. Am J
Cancer Res. 5:20–31. 2015.PubMed/NCBI
|
|
20
|
Nemec KN and Khaled AR: Therapeutic
modulation of apoptosis: Targeting the BCL-2 family at the
interface of the mitochondrial membrane. Yonsei Med J. 49:689–697.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rautureau GJ, Day CL and Hinds MG:
Intrinsically disordered proteins in bcl-2 regulated apoptosis. Int
J Mol Sci. 11:1808–1824. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jiang L, Wang P, Chen L and Chen H:
Down-regulation of FoxM1 by thiostrepton or small interfering RNA
inhibits proliferation, transformation ability and angiogenesis,
and induces apoptosis of nasopharyngeal carcinoma cells. Int J Clin
Exp Pathol. 7:5450–5460. 2014.PubMed/NCBI
|
|
23
|
Ma YP, Zou P, Xiao J and Huang SA:
Expression of survivin in cord blood CD34+
stem/progenitor cells and its significance. Zhonghua Xue Ye Xue Za
Zhi. 24:238–240. 2003.In Chinese. PubMed/NCBI
|
|
24
|
Langelier MF and Pascal JM: PARP-1
mechanism for coupling DNA damage detection to poly(ADP-ribose)
synthesis. Curr Opin Struct Biol. 23:134–143. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Griffin RJ, Pemberton LC, Rhodes D,
Bleasdale C, Bowman K, Calvert AH, Curtin NJ, Durkacz BW, Newell
DR, Porteous JK, et al: Novel potent inhibitors of the DNA repair
enzyme poly(ADP-ribose)polymerase (PARP). Anticancer Drug Des.
10:507–514. 1995.PubMed/NCBI
|
|
26
|
Yang F, Nam S, Zhao R, Tian Y, Liu L,
Horne DA and Jove R: A novel synthetic derivative of the natural
product berbamine inhibits cell viability and induces apoptosis of
human osteosarcoma cells, associated with activation of JNK/AP-1
signaling. Cancer Biol Ther. 14:1024–1031. 2013. View Article : Google Scholar : PubMed/NCBI
|
